In the pharmaceutical and biotechnology industry, ADC stands for Antibody-Drug Conjugate. These represent a sophisticated class of targeted biopharmaceutical medicines designed to treat cancer. An ADC combines the precision targeting capability of a monoclonal antibody—which homes in specifically on antigens expressed on tumor cells—with a potent, cell-killing cytotoxic payload linked together via a stable chemical bridge. This mechanism allows the drug to deliver powerful chemotherapy directly to malignant cells while minimizing systemic exposure and toxic side effects in healthy tissues.